Navigation Links
TOPICA Pharmaceuticals Announces Sublicensing Agreement for Tinea Indication
Date:9/21/2010

PALO ALTO, Calif., Sept. 21 /PRNewswire/ -- TOPICA Pharmaceuticals, Inc. a privately-held biotechnology company, today announced that it has entered into a sublicense and purchase option agreement with an undisclosed partner to develop luliconazole exclusively for tinea infections of the skin in the Americas and Europe. By agreement, additional terms of the deal were not disclosed.

In conjunction with the sublicensing agreement, TOPICA Pharmaceuticals will now focus on developing luliconazole exclusively for the treatment of onychomycosis.  In February of 2010 the company's IND for onychomycosis was opened, paving the way for human clinical trials to begin later in 2010.  

"We are looking forward to the initiation of luliconazole's clinical development program this fall and validating the molecule's promising preclinical profile in onychomycosis.  If the molecule's preclinical profile is validated, luliconazole has the potential to be the first truly effective, safe and convenient topical therapy for onychomycosis; providing physicians and patients with a much needed alternative to currently available oral anti-fungal therapies that have risk of serious adverse events," said Greg Vontz, president & CEO of TOPICA Pharmaceuticals.  

"This is a unique and well aligned transaction that will help to maximize the future potential of the molecule by partnering luliconazole with a well resourced partner and then advancing the molecule in a dedicated effort focused on resolving a long-standing medical need by providing an effective and safe topical therapy for onychomycosis," said Alex Barkas, TOPICA board member and managing director of Prospect Venture Partners.  "We are pleased with the arrangement and the shareholder value we believe will result." TOPICA's existing investors will lead an additional financing for the onychomycosis company.

About Luliconazole

Luliconazole is one of the most potent an
'/>"/>

SOURCE TOPICA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
2. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
3. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
4. Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
5. Topical erectile dysfunction therapy shows promise
6. Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens
7. Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
8. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
9. Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
10. Pilot Study Finds Adding Topical Imiquimod To Laser Therapy Improves The Response Of Port Wine Stain Birthmarks
11. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, Inc., ... Inc. (NASDAQ: SQNM ), the leading ... for next generation noninvasive prenatal tests (NIPT). Through ... technology, called Mantis™, to advance analysis of clinically-relevant ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... 2011 Ingenuity® Systems, a leading provider of ... Medical Center, jointly announced a scientific collaboration using ... As part of the collaboration, Erasmus researchers ... the most impactful biological insights from their NGS ...
... 2011 Accuray Incorporated (Nasdaq: ARAY ), a ... it will report results for its second quarter of fiscal ... after the market closes. A conference call to ... ET and will be hosted by Euan S. Thomson, Ph.D., ...
... the world,s leading provider of medical image analysis services ... Dr. Peter Milner has joined SYNARC to expand and ... solutions for the clinical trial setting. Dr. ... brings over 25 years of experience in drug development ...
Cached Biology Technology:Ingenuity Systems and Erasmus University Medical Center Collaborate on Next-Generation Sequencing Project to Accelerate Disease Research 2Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2011 2SYNARC Engages Dr. Peter Milner for Cardiac Imaging Services and Solutions 2
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
(Date:12/11/2014)... blood pressure plays a role in human health has been ... for high blood pressure – was first described as a ... used in measuring blood pressure was invented in 1896. ... its triggers and its effects. In fact, recent findings have ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... rise, some species of corals are likely to succeed at ... on April 12 in the Cell Press journal Current ... effects on corals. "The good news is that, rather ... change by changing the mix of coral species as the ...
... fit frogs have faster-changing genomes, says a new study ... Stretches of DNA accumulate changes over time, but the ... between species, said author Juan C. Santos of the ... In the past, biologists trying to explain why some ...
... cause hearing damage to Sailors and Marines on flight ... funding a new project to help reduce jet noise, ... into two categories: noise exposure on the flight deck ... said Dr. Brenda Henderson, deputy manager for the Jet ...
Cached Biology News:Under climate change, winners and losers on the coral reef 2Athletic frogs have faster-changing genomes 2ONR taps research teams to help reduce jet noise 2
... reports the data from any one of IITC ... recorder. The final data is sent from the ... is automatic for Systolic, Mean, Heart Rate while ... is always in the position to override the ...
... Custom DNA microarrays designed for your specific ... powerful Paraflo microfluidic synthesis platform. Thousands of ... and LC Sciences can provide assistance with ... as part of our comprehensive Custom DNA ...
... RNA aptamer screening and binding optimization and ... microfluidic on-chip synthesis platform. These microarrays are ... Aptamer Microarray Service. Probe Content ... contains greater than 1500 known aptamer sequences. ...
... for RNA aptamer screening and binding optimization ... Paraflo microfluidic on-chip synthesis platform. Thousands of ... on-chip and LC Sciences can provide assistance ... available as part of our comprehensive DNA/RNA ...
Biology Products: